Market research
CBIO Crescent Biopharma, Inc.
NASDAQ USD Healthcare
Latest close
—
—
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 637M
- P/E ratio
- Not available
- Analyst target
- 30.6
- Dividend yield
- Not available
- Beta
- Not available
Community
Investor discussion
1 comment
Sign in to join the CBIO discussion.
5 years, 4 months ago
Catalyst Biosciences, Inc is currently in a long term downtrend where the price is trading 23.8% below its 200 day moving average.
From a valuation standpoint, the stock is 99.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 4.9.
Catalyst Biosciences, Inc's total revenue rose by inf% to $2M since the same quarter in the previous year.
Its net income has dropped by 38.9% to $-19M since the same quarter in the previous year.
Finally, its free cash flow fell by 173.8% to $-22M since the same quarter in the previous year.
Based on the above factors, Catalyst Biosciences, Inc gets an overall score of 2/5.